Business Context and Reporting Period
Company: Lifecore Biomedical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 6, 2023
Reporting Period: Event date of April 6, 2023
The filing reports the completion of the sale of the Company's O Olive business, as announced in a press release dated April 6, 2023.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a corporate event rather than a financial statement.
Material Changes
- Asset Disposition: The Company completed the sale of its O Olive business on April 6, 2023.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or details on unusual items beyond the announcement of the business sale. The press release referenced in Exhibit 99.1 is not included in the provided text.
Investor Verification Checklist
- Verify the financial terms and consideration received for the sale of the O Olive business.
- Review the impact of the divestiture on the Company's future revenue streams and operational focus.
- Check for any remaining liabilities or contingent obligations associated with the O Olive business post-sale.